<DOC>
	<DOCNO>NCT02143778</DOCNO>
	<brief_summary>This study use train algorithm use Methacetin breath test ( MBT ) measure select cut-off determine presence absence Clinically Significant Portal Hypertension ( CSPH ) define Hepatic Venous Gradient Pressure ( HVPG ) â‰¥ 10mmHg</brief_summary>
	<brief_title>Assessing Portal Hypertension With Methacetin Breath Test</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Hypertension , Portal</mesh_term>
	<criteria>Adult men woman ( &gt; 18 year age ) Known chronic liver disease cirrhosis Europe : Indicated undergo HVPG test US : Consented HVPG For patient treat beta blocker : They stable dose least 6 week prior study related task For patient stop treatment beta blocker : Their last dose least 6 week prior study related task Decompensated cirrhosis clinically define presence ascites , hepatic encephalopathy , variceal bleed hepatorenal syndrome Renal failure ( creatinine &gt; 2.5 mg/dl ) Known acute renal tubular disease Known hypotension ( Systolic Pressure &lt; 100mmHg ) Hypocoagulablity define PT &gt; 6 INR &gt; 2.3 . Congestive heart failure ( assess clinically NIHA &gt; 2 ) Known pulmonary hypertension ( right ventricular systolic pressure &gt; 45 mm Hg ) Uncontrolled diabetes mellitus ( HBA1C &gt; 9.5gr % ) Concurrent prednisone immunosuppressive treatment , therapy and/or response treatment stable least 3 month . Documented suspect hepatocellular carcinoma Gastric bypass surgery extensive small bowel resection Total parenteral nutrition Any organ transplant recipient Pregnant breast feeding Allergy acetaminophen and/or related medication Documented drugrelated concurrent hepatotoxicity drugrelated silent steatosis drugrelated fibrosis ( e.g . amiodarone , methotrexate tamoxifen ) Uncontrolled malabsorption diarrhea Documented noncirrhotic PHT , partial / complete portal venous occlusion , hepatic venous occlusion , previous PHT surgery , placement transjugular intrahepatic portosystemic shunt ( TIPS ) Primary secondary biliary cirrhosis , primary secondary sclerosing cholangitis , hepatic sarcoidosis , cholestatic disorder Subjects unable perform MBT within 7 day HVPG procedure . Subject take follow least 48 hour prior breath test : Acyclovir , allopurinol , amiodarone , carbamazepine , cimetidine , ciprofloxacin , daidzein , ( herbal ) disulfiram , echinacea , enoxacin , famotidine , fluvoxamine , methoxsalen , mexiletine , montelukast , norfloxacin , phenylpropanolamine , phenytoin , propafenone , rifampin , terbinafine , ticlopidine , thiabendazole , verapamil , zileuton oral contraceptive medication might interfere Methacetin metabolism might affect CYP 1A2 Subject take amiodarone statins within last 30 day prior breath test HVPG procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>MBT</keyword>
	<keyword>CSPH</keyword>
	<keyword>HVPG</keyword>
</DOC>